Inhibrx, Inc. (NASDAQ:INBX) Stock Holdings Increased by GAMMA Investing LLC

GAMMA Investing LLC boosted its position in Inhibrx, Inc. (NASDAQ:INBX) by 9,834.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,855 shares of the company’s stock after buying an additional 6,786 shares during the quarter. GAMMA Investing LLC’s holdings in Inhibrx were worth $960,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Sanofi acquired a new position in Inhibrx in the fourth quarter valued at approximately $17,832,000. HighTower Advisors LLC acquired a new position in Inhibrx in the fourth quarter valued at approximately $12,039,000. Walleye Capital LLC acquired a new position in Inhibrx in the fourth quarter valued at approximately $8,932,000. Slotnik Capital LLC acquired a new position in Inhibrx in the fourth quarter valued at approximately $5,975,000. Finally, Millennium Management LLC acquired a new position in Inhibrx in the fourth quarter valued at approximately $3,979,000. 82.46% of the stock is currently owned by institutional investors and hedge funds.

Inhibrx Price Performance

INBX opened at $14.62 on Tuesday. The company has a market capitalization of $211.64 million and a price-to-earnings ratio of 0.13. Inhibrx, Inc. has a 1-year low of $10.80 and a 1-year high of $17.79. The business has a 50 day moving average price of $12.55 and a two-hundred day moving average price of $13.40.

Inhibrx (NASDAQ:INBX) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.55) by ($0.25). Equities analysts expect that Inhibrx, Inc. will post 104.88 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, JMP Securities reiterated a “market perform” rating on shares of Inhibrx in a research report on Thursday, May 15th.

Inhibrx Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.